Actavia Life Sciences, Inc. (RASP)
OTCMKTS · Delayed Price · Currency is USD
0.0005
-0.0095 (-95.00%)
At close: Dec 26, 2025
Actavia Life Sciences Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | Sep '19 Sep 30, 2019 |
Cash & Equivalents | 0 | 0.07 | 0.04 | 0.01 | 0.01 | 0.05 |
Cash & Short-Term Investments | 0 | 0.07 | 0.04 | 0.01 | 0.01 | 0.05 |
Cash Growth | -37.33% | 90.50% | 262.86% | -23.83% | -71.56% | 17.27% |
Prepaid Expenses | 0.05 | 0.02 | 0.05 | 0.03 | 0.02 | 0.01 |
Other Current Assets | - | - | - | - | 0 | 0.01 |
Total Current Assets | 0.05 | 0.1 | 0.09 | 0.04 | 0.03 | 0.07 |
Property, Plant & Equipment | - | - | - | - | 0 | 0 |
Goodwill | - | - | - | - | - | 2.72 |
Other Intangible Assets | - | - | - | - | - | 2.15 |
Total Assets | 0.05 | 0.1 | 0.09 | 0.04 | 0.03 | 4.95 |
Liabilities
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | Sep '19 Sep 30, 2019 |
Accounts Payable | 1.5 | 0.96 | 0.82 | 0.9 | 0.95 | 0.86 |
Accrued Expenses | 0.42 | 0.88 | 0.72 | 1.18 | 1.23 | 1.28 |
Short-Term Debt | 0.3 | 0.21 | 0.13 | 0.68 | 0.52 | 0.26 |
Other Current Liabilities | 0 | 0 | 0.01 | 0.04 | - | - |
Total Current Liabilities | 2.23 | 2.05 | 1.68 | 2.8 | 2.71 | 2.41 |
Long-Term Debt | - | - | 0.09 | - | - | - |
Total Liabilities | 2.23 | 2.05 | 1.77 | 2.8 | 2.71 | 2.41 |
Shareholders' Equity
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | Sep '19 Sep 30, 2019 |
Common Stock | 0.77 | 0.77 | 0.18 | 0.07 | 0.07 | 0.07 |
Additional Paid-In Capital | 25.95 | 25.94 | 22.35 | 20.71 | 19.91 | 19.78 |
Retained Earnings | -28.91 | -28.66 | -24.22 | -23.53 | -22.66 | -17.31 |
Shareholders' Equity | -2.18 | -1.96 | -1.69 | -2.75 | -2.67 | 2.54 |
Total Liabilities & Equity | 0.05 | 0.1 | 0.09 | 0.04 | 0.03 | 4.95 |
Additional Metrics
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | Sep '19 Sep 30, 2019 |
Total Debt | 0.3 | 0.21 | 0.22 | 0.68 | 0.52 | 0.26 |
Net Cash (Debt) | -0.3 | -0.14 | -0.18 | -0.67 | -0.51 | -0.21 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.00 |
Filing Date Shares Outstanding | 771.81 | 771.81 | 771.81 | 179.98 | 68.91 | 68.91 |
Total Common Shares Outstanding | 771.81 | 771.81 | 179.98 | 68.91 | 68.91 | 68.91 |
Working Capital | -2.18 | -1.96 | -1.6 | -2.75 | -2.68 | -2.34 |
Book Value Per Share | -0.00 | -0.00 | -0.01 | -0.04 | -0.04 | 0.04 |
Tangible Book Value | -2.18 | -1.96 | -1.69 | -2.75 | -2.67 | -2.34 |
Tangible Book Value Per Share | -0.00 | -0.00 | -0.01 | -0.04 | -0.04 | -0.03 |